Characteristics of baseline and early therapy (Medium–low)a | Combined multivariate analyses | ||
---|---|---|---|
Refractory, % (n/N) | OR (95% CI) | P value | |
Age, year | |||
 ≥ 36 | 35.0 (43/123) | Reference |  |
 < 36 | 55.0 (60/109) | 1.8 (1.0–3.4) | 0.054 |
GO, n (%) | |||
 Yes | 57.4 (31/54) | 2.0 (1.0–4.2) | 0.060 |
 No | 40.4 (72/178) | Reference |  |
Initial goiter size (cm3) | |||
 ≥ 11.5 | 52.5 (93/177) | 5.2 (2.2–12.6) |  < 0.001 |
 < 11.5 | 18.2 (10/55) | Reference |  |
Initial fT3 (pmol/L) | |||
 ≥ 31.3 | 63.3 (31/49) | 1.8 (0.6–5.3) | 0.289 |
< 31.3 | 39.3 (72/183) | Reference |  |
Initial fT4 (pmol/L) | |||
 ≥ 67.7 | 58.8 (40/68) | 1.8 (0.7–5.1) | 0.244 |
 < 67.7 | 38.4 (63/164) | Reference |  |
Initial TRAb (IU/L) | |||
 ≥ 17.5 | 68.8 (44/64) | 3.0 (1.1–8.5) | 0.036 |
 < 17.5 | 35.1 (59/168) | Reference |  |
fT4 (3Â m)b (pmol/L) | |||
 ≥ 21.0 | 57.5 (50/87) | 1.2 (0.6–2.4) | 0.536 |
 < 21.0 | 36.6 (53/145) | Reference |  |
fT4 (3Â m percentage decrease)c (%) | |||
 ≥ 54.6 | 39.5 (62/157) | Reference |  |
 < 54.6 | 54.7 (41/75) | 3.7 (1.7–7.9) | 0.001 |
TRAb (3Â m accumulation)d (day* IU/L) | |||
 ≥ 1051.5 | 62.0 (49/79) | 1.2 (0.4–3.0) | 0.775 |
 < 1051.5 | 35.3 (54/153) | Reference |  |